LexacalcitolVitamin D analog CAS# 131875-08-6 |
- Leucovorin Calcium
Catalog No.:BCC1198
CAS No.:6035-45-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 131875-08-6 | SDF | Download SDF |
| PubChem ID | 5288670 | Appearance | Powder |
| Formula | C29H48O4 | M.Wt | 460.69 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | KH 106; KH 1060 | ||
| Solubility | DMSO | ||
| Chemical Name | (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol | ||
| SMILES | CCC(CC)(CCCOC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O | ||
| Standard InChIKey | KLZOTDOJMRMLDX-YBBVPDDNSA-N | ||
| Standard InChI | InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Lexacalcitol (KH1060) is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3], as judged by in vitro antiproliferative and cell differentiating assays.
IC50 value:
Target:
KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3. Certain hydroxylated metabolites of KH1060 retained significant biological activity in vitamin D-dependent reporter gene systems (chloramphenicol acetyltransferase). KH 1060 inhibited PBMC proliferation and decreased TNF-alpha levels in IBD patients and this effect was synergistic with anti-TNF-alpha. VDR protein levels were significantly increased by PBMC treatment with KH 1060 or anti-TNF-alpha or their combination in ulcerative colitis (UC) patients, and decreased in Crohn's disease (CD) patients, treating the cells with KH 1060. A synergistic inhibition was registered combining KH 1060 and anti-TNF, at well-defined concentrations. 0.1 nM KH 1060 produced a significant decrease in TNF-alpha levels, determined by ELISA, although less remarkable than in the presence of anti-TNF. References: | |||||
Lexacalcitol Dilution Calculator
Lexacalcitol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1707 mL | 10.8533 mL | 21.7066 mL | 43.4131 mL | 54.2664 mL |
| 5 mM | 0.4341 mL | 2.1707 mL | 4.3413 mL | 8.6826 mL | 10.8533 mL |
| 10 mM | 0.2171 mL | 1.0853 mL | 2.1707 mL | 4.3413 mL | 5.4266 mL |
| 50 mM | 0.0434 mL | 0.2171 mL | 0.4341 mL | 0.8683 mL | 1.0853 mL |
| 100 mM | 0.0217 mL | 0.1085 mL | 0.2171 mL | 0.4341 mL | 0.5427 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lexacalcitol (KH1060) is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3], as judged by in vitro antiproliferative and cell differentiating assays.
- (R,R)-2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine
Catalog No.:BCC8396
CAS No.:131864-67-0
- Aphagranin A
Catalog No.:BCN6889
CAS No.:1318173-53-3
- Cardenolide B-1
Catalog No.:BCN4714
CAS No.:1318158-89-2
- Ugaxanthone
Catalog No.:BCN6775
CAS No.:13179-11-8
- DAU 5884 hydrochloride
Catalog No.:BCC7263
CAS No.:131780-48-8
- Flavopiridol hydrochloride
Catalog No.:BCC3925
CAS No.:131740-09-5
- Urolignoside
Catalog No.:BCN6758
CAS No.:131723-83-6
- Arbidol HCl
Catalog No.:BCC3722
CAS No.:131707-23-8
- (R)-(-)-4-Benzyl-3-propionyl-2-oxazolidinone
Catalog No.:BCC8392
CAS No.:131685-53-5
- Parsonsianine
Catalog No.:BCN2110
CAS No.:131683-36-8
- 8-(1-Chloro-2-hydroxy-3-methylbut-3-enyl)-7-methoxycoumarin
Catalog No.:BCN7058
CAS No.:131652-35-2
- Turmeronol A
Catalog No.:BCN6777
CAS No.:131651-37-1
- (3R)-(+)-1-Benzyl-3-(tert-butoxycarbonylamino)pyrrolidine
Catalog No.:BCC8389
CAS No.:131878-23-4
- 2-Hydroxyethyl Salicylate
Catalog No.:BCN3579
CAS No.:87-28-5
- Fudosteine
Catalog No.:BCC4661
CAS No.:13189-98-5
- Goitrin
Catalog No.:BCN2764
CAS No.:13190-34-6
- Solanesol
Catalog No.:BCN2596
CAS No.:13190-97-1
- Paricalcitol
Catalog No.:BCC1839
CAS No.:131918-61-1
- 1,3,6,8-tetrahydroxy-4-(3-methyl-2-buten-1-yl)-9H-Xanthen-9-one
Catalog No.:BCN1585
CAS No.:1319198-98-5
- CC0651
Catalog No.:BCC4200
CAS No.:1319207-44-7
- 3,6,19-Trihydroxy-23-oxo-12-ursen-28-oic acid
Catalog No.:BCN1584
CAS No.:131984-82-2
- Shizukaol A
Catalog No.:BCN6984
CAS No.:131984-98-0
- Benztropine mesylate
Catalog No.:BCC4524
CAS No.:132-17-2
- Diphenylpyraline HCl
Catalog No.:BCC3768
CAS No.:132-18-3
Characterization of irritant patch test reactions to topical D vitamins and all-trans retinoic acid in comparison with sodium lauryl sulphate. Evaluation by clinical scoring and multiparametric non-invasive measuring techniques.[Pubmed:9292072]
Br J Dermatol. 1997 Aug;137(2):234-40.
The study was a single-centre, double-blind randomized, placebo-controlled within-subject comparison of 42 healthy volunteers. Occlusive patch test for 48 h was performed with solutions of 1 alpha,25(OH)2D3 (calcitriol), two vitamin D analogues (calcipotriol and KH 1060 (Lexacalcitol)), all-trans retinoic acid and sodium lauryl sulphate (SLS) as reference irritant. Solution vehicles and an empty chamber was also included. Test evaluation was performed at day 2, day 3 and again on day 7. Test evaluation was based both on clinical scoring and on various non-invasive measuring methods. 1 alpha,25(OH)2D3, calcipotriol and KH 1060 all showed mild irritation in the concentrations tested. The number and severity of test reactions was found to be dose dependent based both on clinical scoring and on non-invasive measurements. Irritation of the vitamin D analogues mainly affected the vasculature with vasodilation and increased cutaneous blood flow. All-trans retinoic acid showed irritant reactions with some similarity to the tested vitamin D analogues; however, the reactions were more prolonged. Transepidermal water loss (TEWL) was affected neither after application of vitamin D analogues nor after application of all-trans retinoic acid and it was thus concluded that these substances are non-corrosive. SLS showed the known irritant mechanism with corrosion and increase in TEWL as the primary event.
The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity.[Pubmed:9389535]
Endocrinology. 1997 Dec;138(12):5485-96.
Vitamin D analogs are valuable drugs with established and potential uses in hyperproliferative disorders. Lexacalcitol (KH1060) is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3], as judged by in vitro antiproliferative and cell differentiating assays. The underlying biochemical reasons for the increased biological activity of KH1060 are unknown, but are thought to include 1) metabolic considerations in addition to explanations based upon 2) enhanced stability of KH1060-liganded transcriptional complexes. In this study we explored the in vivo and in vitro metabolism of KH1060. We established by physicochemical techniques the existence of multiple side-chain hydroxylated metabolites of KH1060, including 24-, 24a-, 26-, and 26a-hydroxylated derivatives as well as side-chain truncated forms. KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3. Certain hydroxylated metabolites of KH1060 retained significant biological activity in vitamin D-dependent reporter gene systems (chloramphenicol acetyltransferase). Likewise, those metabolites accumulating in the target cell culture models in metabolism studies, particularly 24a-hydroxy-KH1060 and 26-hydroxy-KH1060, retained biological activities superior to those of 1alpha,25-(OH)2D3 in native gene expression systems in vitamin D target cells (osteopontin and P450cc24). We conclude that KH1060 is rapidly metabolized by a variety of cytochrome P450-mediated enzyme systems to products, many of which retain significant biological activity in vitamin D-dependent assay systems. These results provide an explanation for the considerable biological activity advantage displayed by KH1060 compared with 1alpha,25-(OH)2D3 in various in vitro assay systems.
